Sucralfate and Warfarin
Authors: Dennis Mungall, Robert L. Talbert, Charles Phillips, Daniel Jaffe, Thomas M. Ludden
Journal: Annals of Internal Medicine (1983)

Letters and Corrections1 April 1983Sucralfate and WarfarinDENNIS MUNGALL, PHARM. D., ROBERT L. TALBERT, PHARM. D., CHARLES PHILLIPS, M.D., DANIEL JAFFE, M.D., THOMAS M. LUDDEN, PH.DDENNIS MUNGALL, PHARM. D., ROBERT L. TALBERT, PHARM. D., CHARLES PHILLIPS, M.D., DANIEL JAFFE, M.D., THOMAS M. LUDDEN, PH.DAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-98-4-557_2 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: Sucralfate has recently been introduced for the treatment of duodenal peptic ulcer disease (1). Little information is available on the interaction in humans of sucralfate and other drugs (2). The present case may represent an interaction of warfarin and sucralfate.A 59-year-old man was admitted to the coronary care unit on 27 July 1982 to rule out myocardial infarction. The patient's medical history included a previous myocardial infarction in 1981 complicated by mural thrombus peptic ulcer disease, and adult onset diabetes. Admission medications included chlorpropamide, 250 mg/d; digoxin, 0.25 mg/d; furosemide, 40 mg/d; potassium chloride, 40 meq/d;...References1. GARNETT W. Sucralfate: alternative therapy for peptic ulcer disease. Clin Pharm. 1982;1:307-14. MedlineGoogle Scholar2. RICHARDSON C. Sucralfate. Ann Intern Med. 1982;97:269-72. LinkGoogle Scholar3. WINTROBE M. The hereditary coagulation disorders. In: WINTROBE MM, ed. Clinical Hematology. Philadelphia: Lea and Febiger; 1974; 1184. Google Scholar4. ROBINSONBENJAMINMCCORMACK DDJ. Interaction of warfarin and nonsystemic gastrointestinal drugs. Clin Pharmacol Ther. 1971;12:491-5. CrossrefMedlineGoogle Scholar5. WONGMUNGALLLUDDENMCCLEMORE YDTT. Overanti-coagulation associated with severe heart failure: a case report. Presented at the 17th Annual American Society of Hospital Pharmacists Midyear Clinical Meeting, Los Angeles, California, 1982. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: The University of Texas at Austin University of Texas Health Science Center at San Antonio San Antonio, TX 78284 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byCoumarin anticoagulantsANTICOAGULANTS, THROMBOLYTIC AGENTS, AND ANTI-PLATELET DRUGSCoumarin anticoagulantsINTERACTIONS OF WARFARINSucralfate Drug Interaction StudiesSucralfate—Warfarin InteractionPharmacokinetics in the elderlyAltered Absorption of Digoxin, Sustained-Release Quinidine, and Warfarin with Sucralfate AdministrationSucralfate—Safety and Side EffectsSucralfate—Warfarin InteractionSucralfate in the Prophylaxis and Treatment of Stress-Induced BleedingPEPTIC ULCERDrug-Antacid Interactions: Assessment of Clinical ImportanceEffect of Sucralfate on the Absorption and Pharmacokinetics of ChlorpropamideThe influence of sucralfate on ibuprofen absorption in healthy adult malesCimetidine absorption in humans during sucralfate coadministration.The effects of sucralfate upon phenytoin absorption in man.Clinically significant sucralfate-warfarin interaction is not likely [letter]Sucralfate: développement d'un nouveau concept de la thérapeutique antiulcéreuseDrugs affecting blood clotting and hemostasis 1 April 1983Volume 98, Issue 4Page: 557-557KeywordsCardiac care unitDrug interactionsDrugsMyocardial infarctionPeptic ulcersPotassium chlorideThrombosisType 2 diabetes Issue Published: 1 April 1983 PDF downloadLoading ...